Samsung Biologics announced Monday that it will invest 7 trillion won ($4.8 billion) to construct its third bio campus in Songdo, Incheon, securing the world’s largest biopharmaceutical production capacity and expanding into next-generation modality contract development and manufacturing (CDMO) services.
The company said it has signed a land purchase agreement with the Incheon Free Economic Zone Authority (IFEZA) for 187,427 square meters of industrial land within the Songdo Zone 11 Advanced Industry Cluster, valued at 248.7 billion won. The site is a centerpiece of Incheon City’s “Bio Cluster Activation” strategy, marking a key milestone in establishing a high-tech ecosystem centered on global CDMO leadership.
Samsung Biologics currently operates Plants 1 through 5 at its first bio campus, offering a total antibody drug production capacity of 784,000 liters. When Plants 6 through 8 at the second campus are completed, the company’s overall capacity will rise by an additional 540,000 liters, reaching 1.324 million liters—the world’s largest biomanufacturing capacity at a single site. The addition of the third campus will further expand this mega-scale production belt to encompass next-generation modalities, including cell and gene therapies (CGTs), peptide-based medicines, and antibody vaccines.
The new campus will be developed in two stages, spanning from 2025 to 2034. Four major facilities will be constructed sequentially to integrate R&D and production capabilities for advanced modalities. The company expects to create over 10,000 direct and indirect jobs and generate an estimated 12 trillion won in total economic impact by 2030.
The company said it has signed a land purchase agreement with the Incheon Free Economic Zone Authority (IFEZA) for 187,427 square meters of industrial land within the Songdo Zone 11 Advanced Industry Cluster, valued at 248.7 billion won. The site is a centerpiece of Incheon City’s “Bio Cluster Activation” strategy, marking a key milestone in establishing a high-tech ecosystem centered on global CDMO leadership.
Samsung Biologics currently operates Plants 1 through 5 at its first bio campus, offering a total antibody drug production capacity of 784,000 liters. When Plants 6 through 8 at the second campus are completed, the company’s overall capacity will rise by an additional 540,000 liters, reaching 1.324 million liters—the world’s largest biomanufacturing capacity at a single site. The addition of the third campus will further expand this mega-scale production belt to encompass next-generation modalities, including cell and gene therapies (CGTs), peptide-based medicines, and antibody vaccines.
The new campus will be developed in two stages, spanning from 2025 to 2034. Four major facilities will be constructed sequentially to integrate R&D and production capabilities for advanced modalities. The company expects to create over 10,000 direct and indirect jobs and generate an estimated 12 trillion won in total economic impact by 2030.
이 기사의 카테고리는 언론사의 분류를 따릅니다.